JP2016503427A - 防腐剤 - Google Patents
防腐剤 Download PDFInfo
- Publication number
- JP2016503427A JP2016503427A JP2015543520A JP2015543520A JP2016503427A JP 2016503427 A JP2016503427 A JP 2016503427A JP 2015543520 A JP2015543520 A JP 2015543520A JP 2015543520 A JP2015543520 A JP 2015543520A JP 2016503427 A JP2016503427 A JP 2016503427A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- particles
- active agent
- terpene
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003755 preservative agent Substances 0.000 title claims description 50
- 230000002335 preservative effect Effects 0.000 title claims description 44
- 239000000203 mixture Substances 0.000 claims abstract description 185
- 235000007586 terpenes Nutrition 0.000 claims abstract description 179
- 150000003505 terpenes Chemical class 0.000 claims abstract description 178
- 239000013543 active substance Substances 0.000 claims abstract description 144
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 26
- 239000002245 particle Substances 0.000 claims description 238
- 229920001503 Glucan Polymers 0.000 claims description 110
- 239000011859 microparticle Substances 0.000 claims description 105
- 238000000034 method Methods 0.000 claims description 93
- 210000005253 yeast cell Anatomy 0.000 claims description 84
- 210000002421 cell wall Anatomy 0.000 claims description 58
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 56
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 47
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 46
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims description 44
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 42
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims description 41
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 37
- 229940043350 citral Drugs 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 33
- 239000005844 Thymol Substances 0.000 claims description 28
- 229960000790 thymol Drugs 0.000 claims description 28
- 241000607479 Yersinia pestis Species 0.000 claims description 26
- 239000002917 insecticide Substances 0.000 claims description 24
- -1 pinene Chemical compound 0.000 claims description 24
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 23
- 239000005770 Eugenol Substances 0.000 claims description 23
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 23
- 229960002217 eugenol Drugs 0.000 claims description 23
- 229920002498 Beta-glucan Polymers 0.000 claims description 22
- 239000005792 Geraniol Substances 0.000 claims description 22
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims description 22
- 206010035148 Plague Diseases 0.000 claims description 22
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 claims description 22
- 229940113087 geraniol Drugs 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 20
- 239000003094 microcapsule Substances 0.000 claims description 20
- 239000005973 Carvone Substances 0.000 claims description 19
- 239000004094 surface-active agent Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 14
- 230000000843 anti-fungal effect Effects 0.000 claims description 14
- 229940121375 antifungal agent Drugs 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- 230000012010 growth Effects 0.000 claims description 13
- 239000000417 fungicide Substances 0.000 claims description 11
- 230000002147 killing effect Effects 0.000 claims description 11
- 241000238421 Arthropoda Species 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000002538 fungal effect Effects 0.000 claims description 10
- 241000233866 Fungi Species 0.000 claims description 9
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 8
- 239000002502 liposome Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000004005 microsphere Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 239000010419 fine particle Substances 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 239000004009 herbicide Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 230000002363 herbicidal effect Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- PSQYTAPXSHCGMF-BQYQJAHWSA-N β-ionone Chemical compound CC(=O)\C=C\C1=C(C)CCCC1(C)C PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 claims description 5
- 241000239290 Araneae Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 241000282898 Sus scrofa Species 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 claims description 4
- 230000000855 fungicidal effect Effects 0.000 claims description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 4
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 claims description 4
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 3
- 241000601180 Clematis villosa Species 0.000 claims description 3
- 241001600609 Equus ferus Species 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 230000000749 insecticidal effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 2
- 229930007631 (-)-perillyl alcohol Natural products 0.000 claims description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims description 2
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 claims description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 2
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 2
- 241000723346 Cinnamomum camphora Species 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 241000282327 Felis silvestris Species 0.000 claims description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 2
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 claims description 2
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 claims description 2
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 claims description 2
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 claims description 2
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 claims description 2
- 229940011037 anethole Drugs 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 2
- 229940116229 borneol Drugs 0.000 claims description 2
- 229930008380 camphor Natural products 0.000 claims description 2
- 229960000846 camphor Drugs 0.000 claims description 2
- 150000001746 carotenes Chemical class 0.000 claims description 2
- 235000005473 carotenes Nutrition 0.000 claims description 2
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 2
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 2
- 235000007746 carvacrol Nutrition 0.000 claims description 2
- 229930007927 cymene Natural products 0.000 claims description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229930002886 farnesol Natural products 0.000 claims description 2
- 229940043259 farnesol Drugs 0.000 claims description 2
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 2
- 235000001510 limonene Nutrition 0.000 claims description 2
- 229940087305 limonene Drugs 0.000 claims description 2
- 229930007744 linalool Natural products 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 claims description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 claims description 2
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 claims description 2
- 235000005693 perillyl alcohol Nutrition 0.000 claims description 2
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 claims description 2
- 239000005648 plant growth regulator Substances 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 229930003802 tocotrienol Natural products 0.000 claims description 2
- 239000011731 tocotrienol Substances 0.000 claims description 2
- 235000019148 tocotrienols Nutrition 0.000 claims description 2
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims 1
- 230000000361 pesticidal effect Effects 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 52
- 102000004169 proteins and genes Human genes 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 108090000765 processed proteins & peptides Chemical class 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000003463 hyperproliferative effect Effects 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229920000057 Mannan Polymers 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Aalpha Natural products C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 2
- YFLDZPUXCOSOGU-UHFFFAOYSA-N 1-iodoprop-2-ynyl n-butylcarbamate Chemical compound CCCCNC(=O)OC(I)C#C YFLDZPUXCOSOGU-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000000895 acaricidal effect Effects 0.000 description 2
- 239000000642 acaricide Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002036 drum drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 150000002506 iron compounds Chemical class 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- JWZXKXIUSSIAMR-UHFFFAOYSA-N methylene bis(thiocyanate) Chemical compound N#CSCSC#N JWZXKXIUSSIAMR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000002728 pyrethroid Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 229960004249 sodium acetate Drugs 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- ZCVAOQKBXKSDMS-PVAVHDDUSA-N (+)-trans-(S)-allethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(CC=C)C(=O)C1 ZCVAOQKBXKSDMS-PVAVHDDUSA-N 0.000 description 1
- ZCVAOQKBXKSDMS-AQYZNVCMSA-N (+)-trans-allethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(CC=C)C(=O)C1 ZCVAOQKBXKSDMS-AQYZNVCMSA-N 0.000 description 1
- CXBMCYHAMVGWJQ-CABCVRRESA-N (1,3-dioxo-4,5,6,7-tetrahydroisoindol-2-yl)methyl (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCN1C(=O)C(CCCC2)=C2C1=O CXBMCYHAMVGWJQ-CABCVRRESA-N 0.000 description 1
- KAATUXNTWXVJKI-NSHGMRRFSA-N (1R)-cis-(alphaS)-cypermethrin Chemical compound CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-NSHGMRRFSA-N 0.000 description 1
- SBNFWQZLDJGRLK-RTWAWAEBSA-N (1R)-trans-phenothrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-RTWAWAEBSA-N 0.000 description 1
- YATDSXRLIUJOQN-SVRRBLITSA-N (2,3,4,5,6-pentafluorophenyl)methyl (1r,3s)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(Cl)Cl)[C@H]1C(=O)OCC1=C(F)C(F)=C(F)C(F)=C1F YATDSXRLIUJOQN-SVRRBLITSA-N 0.000 description 1
- RYAUSSKQMZRMAI-ALOPSCKCSA-N (2S,6R)-4-[3-(4-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine Chemical compound C=1C=C(C(C)(C)C)C=CC=1CC(C)CN1C[C@H](C)O[C@H](C)C1 RYAUSSKQMZRMAI-ALOPSCKCSA-N 0.000 description 1
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- ZFHGXWPMULPQSE-SZGBIDFHSA-N (Z)-(1S)-cis-tefluthrin Chemical compound FC1=C(F)C(C)=C(F)C(F)=C1COC(=O)[C@@H]1C(C)(C)[C@@H]1\C=C(/Cl)C(F)(F)F ZFHGXWPMULPQSE-SZGBIDFHSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- TUBQDCKAWGHZPF-UHFFFAOYSA-N 1,3-benzothiazol-2-ylsulfanylmethyl thiocyanate Chemical compound C1=CC=C2SC(SCSC#N)=NC2=C1 TUBQDCKAWGHZPF-UHFFFAOYSA-N 0.000 description 1
- PXMNMQRDXWABCY-UHFFFAOYSA-N 1-(4-chlorophenyl)-4,4-dimethyl-3-(1H-1,2,4-triazol-1-ylmethyl)pentan-3-ol Chemical class C1=NC=NN1CC(O)(C(C)(C)C)CCC1=CC=C(Cl)C=C1 PXMNMQRDXWABCY-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- FMTFEIJHMMQUJI-NJAFHUGGSA-N 102130-98-3 Natural products CC=CCC1=C(C)[C@H](CC1=O)OC(=O)[C@@H]1[C@@H](C=C(C)C)C1(C)C FMTFEIJHMMQUJI-NJAFHUGGSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- RULKYXXCCZZKDZ-UHFFFAOYSA-N 2,3,4,5-tetrachlorophenol Chemical compound OC1=CC(Cl)=C(Cl)C(Cl)=C1Cl RULKYXXCCZZKDZ-UHFFFAOYSA-N 0.000 description 1
- SFOKDWPZOYRZFF-UHFFFAOYSA-H 2,3-dihydroxybutanedioate;iron(3+) Chemical compound [Fe+3].[Fe+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O SFOKDWPZOYRZFF-UHFFFAOYSA-H 0.000 description 1
- BSWWXRFVMJHFBN-UHFFFAOYSA-N 2,4,6-tribromophenol Chemical compound OC1=C(Br)C=C(Br)C=C1Br BSWWXRFVMJHFBN-UHFFFAOYSA-N 0.000 description 1
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 1
- YTOPFCCWCSOHFV-UHFFFAOYSA-N 2,6-dimethyl-4-tridecylmorpholine Chemical compound CCCCCCCCCCCCCN1CC(C)OC(C)C1 YTOPFCCWCSOHFV-UHFFFAOYSA-N 0.000 description 1
- STMIIPIFODONDC-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol Chemical class C=1C=C(Cl)C=C(Cl)C=1C(O)(CCCC)CN1C=NC=N1 STMIIPIFODONDC-UHFFFAOYSA-N 0.000 description 1
- UFNOUKDBUJZYDE-UHFFFAOYSA-N 2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol Chemical class C1=NC=NN1CC(O)(C=1C=CC(Cl)=CC=1)C(C)C1CC1 UFNOUKDBUJZYDE-UHFFFAOYSA-N 0.000 description 1
- NUPJIGQFXCQJBK-UHFFFAOYSA-N 2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-5-(methoxymethyl)nicotinic acid Chemical compound OC(=O)C1=CC(COC)=CN=C1C1=NC(C)(C(C)C)C(=O)N1 NUPJIGQFXCQJBK-UHFFFAOYSA-N 0.000 description 1
- CLQMBPJKHLGMQK-UHFFFAOYSA-N 2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)nicotinic acid Chemical compound N1C(=O)C(C(C)C)(C)N=C1C1=NC=CC=C1C(O)=O CLQMBPJKHLGMQK-UHFFFAOYSA-N 0.000 description 1
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
- NCKMMSIFQUPKCK-UHFFFAOYSA-N 2-benzyl-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1CC1=CC=CC=C1 NCKMMSIFQUPKCK-UHFFFAOYSA-N 0.000 description 1
- IQUCNXSZNHPPML-UHFFFAOYSA-N 2-chloro-n-[(4-chlorophenyl)-phenylmethyl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C(NC(=O)CCl)C1=CC=CC=C1 IQUCNXSZNHPPML-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- HFOCAQPWSXBFFN-UHFFFAOYSA-N 2-methylsulfonylbenzaldehyde Chemical compound CS(=O)(=O)C1=CC=CC=C1C=O HFOCAQPWSXBFFN-UHFFFAOYSA-N 0.000 description 1
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- FSCWZHGZWWDELK-UHFFFAOYSA-N 3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione Chemical compound O=C1C(C)(C=C)OC(=O)N1C1=CC(Cl)=CC(Cl)=C1 FSCWZHGZWWDELK-UHFFFAOYSA-N 0.000 description 1
- PVSGXWMWNRGTKE-UHFFFAOYSA-N 5-methyl-2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]pyridine-3-carboxylic acid Chemical compound N1C(=O)C(C(C)C)(C)N=C1C1=NC=C(C)C=C1C(O)=O PVSGXWMWNRGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000005884 Beta-Cyfluthrin Substances 0.000 description 1
- 239000005874 Bifenthrin Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FAZLUYZITDQJEQ-UHFFFAOYSA-N C#CCOCCC1=CC=CC=C1N(C(=O)O)I Chemical compound C#CCOCCC1=CC=CC=C1N(C(=O)O)I FAZLUYZITDQJEQ-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 239000005747 Chlorothalonil Substances 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000005946 Cypermethrin Substances 0.000 description 1
- 239000005757 Cyproconazole Chemical class 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000005644 Dazomet Substances 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 239000005892 Deltamethrin Substances 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000005504 Dicamba Substances 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010068516 Encapsulation reaction Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000005895 Esfenvalerate Substances 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000005778 Fenpropimorph Substances 0.000 description 1
- 239000005558 Fluroxypyr Substances 0.000 description 1
- 239000005791 Fuberidazole Substances 0.000 description 1
- 239000005903 Gamma-cyhalothrin Substances 0.000 description 1
- 241000134874 Geraniales Species 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000005562 Glyphosate Substances 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100024023 Histone PARylation factor 1 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 101001047783 Homo sapiens Histone PARylation factor 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005566 Imazamox Substances 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 239000005867 Iprodione Substances 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 239000005573 Linuron Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940082819 Luteinizing hormone releasing hormone (LHRH) agonist Drugs 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical compound C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000005591 Pendimethalin Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 239000005595 Picloram Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 239000005820 Prochloraz Chemical class 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000005822 Propiconazole Chemical class 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000005839 Tebuconazole Substances 0.000 description 1
- 239000005939 Tefluthrin Substances 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000005846 Triadimenol Substances 0.000 description 1
- 239000005627 Triclopyr Substances 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VXSIXFKKSNGRRO-MXOVTSAMSA-N [(1s)-2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate;[(1s)-2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-3-[(e)-3-methoxy-2-methyl-3-oxoprop-1-enyl Chemical class CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1.CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VXSIXFKKSNGRRO-MXOVTSAMSA-N 0.000 description 1
- QQODLKZGRKWIFG-RUTXASTPSA-N [(R)-cyano-(4-fluoro-3-phenoxyphenyl)methyl] (1S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)C(C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)C1=CC=C(F)C(OC=2C=CC=CC=2)=C1 QQODLKZGRKWIFG-RUTXASTPSA-N 0.000 description 1
- KAATUXNTWXVJKI-QPIRBTGLSA-N [(s)-cyano-(3-phenoxyphenyl)methyl] 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-QPIRBTGLSA-N 0.000 description 1
- LWZFANDGMFTDAV-WYDSMHRWSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-WYDSMHRWSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940024113 allethrin Drugs 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- AKNQMEBLVAMSNZ-UHFFFAOYSA-N azaconazole Chemical class ClC1=CC(Cl)=CC=C1C1(CN2N=CN=C2)OCCO1 AKNQMEBLVAMSNZ-UHFFFAOYSA-N 0.000 description 1
- 229950000294 azaconazole Drugs 0.000 description 1
- PLKYGPRDCKGEJH-UHFFFAOYSA-N azane;2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound N.[Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O PLKYGPRDCKGEJH-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 description 1
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- OCBHHZMJRVXXQK-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 OCBHHZMJRVXXQK-UHFFFAOYSA-M 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- OMFRMAHOUUJSGP-IRHGGOMRSA-N bifenthrin Chemical compound C1=CC=C(C=2C=CC=CC=2)C(C)=C1COC(=O)[C@@H]1[C@H](\C=C(/Cl)C(F)(F)F)C1(C)C OMFRMAHOUUJSGP-IRHGGOMRSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229950002373 bioresmethrin Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- WTEVQBCEXWBHNA-YFHOEESVSA-N citral B Natural products CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 1
- HUBANNPOLNYSAD-UHFFFAOYSA-N clopyralid Chemical compound OC(=O)C1=NC(Cl)=CC=C1Cl HUBANNPOLNYSAD-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- VHUCFMSCPNJWMT-UHFFFAOYSA-N cyclopentene;4,5-dihydro-1,2-thiazole Chemical compound C1CC=CC1.C1CC=NS1 VHUCFMSCPNJWMT-UHFFFAOYSA-N 0.000 description 1
- 229960001591 cyfluthrin Drugs 0.000 description 1
- QQODLKZGRKWIFG-QSFXBCCZSA-N cyfluthrin Chemical compound CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@@H](C#N)C1=CC=C(F)C(OC=2C=CC=CC=2)=C1 QQODLKZGRKWIFG-QSFXBCCZSA-N 0.000 description 1
- ZXQYGBMAQZUVMI-UNOMPAQXSA-N cyhalothrin Chemical compound CC1(C)C(\C=C(/Cl)C(F)(F)F)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-UNOMPAQXSA-N 0.000 description 1
- 239000001941 cymbopogon citratus dc and cymbopogon flexuosus oil Substances 0.000 description 1
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
- 229960005424 cypermethrin Drugs 0.000 description 1
- 229940008203 d-transallethrin Drugs 0.000 description 1
- NMCCNOZOBBWFMN-UHFFFAOYSA-N davicil Chemical compound CS(=O)(=O)C1=C(Cl)C(Cl)=NC(Cl)=C1Cl NMCCNOZOBBWFMN-UHFFFAOYSA-N 0.000 description 1
- QAYICIQNSGETAS-UHFFFAOYSA-N dazomet Chemical compound CN1CSC(=S)N(C)C1 QAYICIQNSGETAS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960002483 decamethrin Drugs 0.000 description 1
- OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- IWEDIXLBFLAXBO-UHFFFAOYSA-N dicamba Chemical compound COC1=C(Cl)C=CC(Cl)=C1C(O)=O IWEDIXLBFLAXBO-UHFFFAOYSA-N 0.000 description 1
- 229960003887 dichlorophen Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- PGQAXGHQYGXVDC-UHFFFAOYSA-N dodecyl(dimethyl)azanium;chloride Chemical compound Cl.CCCCCCCCCCCCN(C)C PGQAXGHQYGXVDC-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- NYPJDWWKZLNGGM-RPWUZVMVSA-N esfenvalerate Chemical compound C=1C([C@@H](C#N)OC(=O)[C@@H](C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-RPWUZVMVSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229950006668 fenfluthrin Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- DGCPIBPDYFLAAX-YTAGXALCSA-N fertirelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 DGCPIBPDYFLAAX-YTAGXALCSA-N 0.000 description 1
- 108700020627 fertirelin Proteins 0.000 description 1
- 229950001491 fertirelin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- MEFQWPUMEMWTJP-UHFFFAOYSA-N fluroxypyr Chemical compound NC1=C(Cl)C(F)=NC(OCC(O)=O)=C1Cl MEFQWPUMEMWTJP-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZEYJIQLVKGBLEM-UHFFFAOYSA-N fuberidazole Chemical compound C1=COC(C=2N=C3[CH]C=CC=C3N=2)=C1 ZEYJIQLVKGBLEM-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229940097068 glyphosate Drugs 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- ONUFESLQCSAYKA-UHFFFAOYSA-N iprodione Chemical compound O=C1N(C(=O)NC(C)C)CC(=O)N1C1=CC(Cl)=CC(Cl)=C1 ONUFESLQCSAYKA-UHFFFAOYSA-N 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WJZHMLNIAZSFDO-UHFFFAOYSA-N manganese zinc Chemical compound [Mn].[Zn] WJZHMLNIAZSFDO-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- OWWASHBXVFOTDF-UHFFFAOYSA-N n-methyl-1h-imidazole-2-carboxamide Chemical compound CNC(=O)C1=NC=CN1 OWWASHBXVFOTDF-UHFFFAOYSA-N 0.000 description 1
- LBZQAEQLSRWNLM-UHFFFAOYSA-N n-methyl-1h-pyrrole-2-carboxamide Chemical compound CNC(=O)C1=CC=CN1 LBZQAEQLSRWNLM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000001069 nematicidal effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- CHIFOSRWCNZCFN-UHFFFAOYSA-N pendimethalin Chemical compound CCC(CC)NC1=C([N+]([O-])=O)C=C(C)C(C)=C1[N+]([O-])=O CHIFOSRWCNZCFN-UHFFFAOYSA-N 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000490 permethrin Drugs 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960003536 phenothrin Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- NQQVFXUMIDALNH-UHFFFAOYSA-N picloram Chemical compound NC1=C(Cl)C(Cl)=NC(C(O)=O)=C1Cl NQQVFXUMIDALNH-UHFFFAOYSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- TVLSRXXIMLFWEO-UHFFFAOYSA-N prochloraz Chemical class C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl TVLSRXXIMLFWEO-UHFFFAOYSA-N 0.000 description 1
- QXJKBPAVAHBARF-BETUJISGSA-N procymidone Chemical compound O=C([C@]1(C)C[C@@]1(C1=O)C)N1C1=CC(Cl)=CC(Cl)=C1 QXJKBPAVAHBARF-BETUJISGSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical class O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HYJYGLGUBUDSLJ-UHFFFAOYSA-N pyrethrin Natural products CCC(=O)OC1CC(=C)C2CC3OC3(C)C2C2OC(=O)C(=C)C12 HYJYGLGUBUDSLJ-UHFFFAOYSA-N 0.000 description 1
- 229940070846 pyrethrins Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- YBBJKCMMCRQZMA-UHFFFAOYSA-N pyrithione Chemical compound ON1C=CC=CC1=S YBBJKCMMCRQZMA-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940108410 resmethrin Drugs 0.000 description 1
- VEMKTZHHVJILDY-FIWHBWSRSA-N resmethrin Chemical compound CC1(C)[C@H](C=C(C)C)C1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-FIWHBWSRSA-N 0.000 description 1
- 239000003128 rodenticide Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
- 229940079841 sodium copper chlorophyllin Drugs 0.000 description 1
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- WQSRXNAKUYIVET-UHFFFAOYSA-N sulfuric acid;zinc Chemical compound [Zn].OS(O)(=O)=O WQSRXNAKUYIVET-UHFFFAOYSA-N 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960005199 tetramethrin Drugs 0.000 description 1
- 150000003535 tetraterpenes Chemical class 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- HYVWIQDYBVKITD-UHFFFAOYSA-N tolylfluanid Chemical compound CN(C)S(=O)(=O)N(SC(F)(Cl)Cl)C1=CC=C(C)C=C1 HYVWIQDYBVKITD-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YWSCPYYRJXKUDB-KAKFPZCNSA-N tralomethrin Chemical compound CC1(C)[C@@H](C(Br)C(Br)(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 YWSCPYYRJXKUDB-KAKFPZCNSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- BAZVSMNPJJMILC-UHFFFAOYSA-N triadimenol Chemical compound C1=NC=NN1C(C(O)C(C)(C)C)OC1=CC=C(Cl)C=C1 BAZVSMNPJJMILC-UHFFFAOYSA-N 0.000 description 1
- REEQLXCGVXDJSQ-UHFFFAOYSA-N trichlopyr Chemical compound OC(=O)COC1=NC(Cl)=C(Cl)C=C1Cl REEQLXCGVXDJSQ-UHFFFAOYSA-N 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Chemical class 0.000 description 1
- 229930003231 vitamin Chemical class 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000005943 zeta-Cypermethrin Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/22—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients stabilising the active ingredients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
- A01N25/28—Microcapsules or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Insects & Arthropods (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
100%のチモール;
100%のゲラニオール;
100%のオイゲノール;
100%のシトラール;および
100%のL−カルボン。
100%のチモール;
50%のゲラニオールおよび50%のチモール;
50%のオイゲノールおよび50%のチモール;
33%のゲラニオール、33%のオイゲノールおよび33%のチモール;
33%のオイゲノール、33%のチモールおよび33%のシトラール;
25%のゲラニオール、25%のオイゲノール、25%のチモールおよび25%のシトラール;および
20%のゲラニオール、20%のオイゲノール、20%のシトラール、20%のチモールおよび20%のL−カルボン。
受容者に活性な薬剤を送達する方法であって、
(i)防腐性となる量の1種類以上のテルペンを含む微粒子成分を提供する工程と;
(ii)微粒子と活性な薬剤とを接触させ、この活性な薬剤が、少なくとも部分的に微粒子内に封入されるようになる工程と;
(iii)受容者と、活性な薬剤を封入する微粒子成分とを接触させる工程とを含む、方法を提供する。
−活性な薬剤の封入を最大にする。
−封入されていない活性な薬剤を最小限にする。
−活性な薬剤の安定性を制御する。
−活性な薬剤の放出速度を制御する。
−質量および均質性を増加させるために、液体活性な薬剤の固体形態の作成。
−活性な薬剤の取扱いおよび塗布を単純化する。
−活性な薬剤の臭気および味をマスキングする。
−望ましくないカビ、酵母および/または真菌類の成長に起因する組成物の腐敗または分解を阻害する。
微粒子、例えば、β−グルカンを含む抽出された酵母細胞壁を提供し、酵母細胞壁が内部空間の輪郭を形成する工程と;
微粒子と防腐性となる量のテルペン成分とを接触させ、テルペン成分が微粒子と会合するようになる工程と;
微粒子と活性な薬剤とを接触させ、活性な薬剤が微粒子と会合するようになる工程とを含む、方法も提供する。
(a)テルペン成分を提供する工程と;
(b)微粒子、例えば、中空のグルカン粒子または細胞壁粒子を提供する工程と;
(c)適切な条件下、例えば、テルペンを封入するために、テルペン成分を微粒子と共にインキュベートする工程と;
(d)場合により、微粒子/テルペン成分を回収する工程と;
(e)活性な薬剤成分を提供する工程と;
(f)適切な条件下、例えば、テルペンを封入するために、活性な薬剤を微粒子と共にインキュベートする工程と;
(g)微粒子/テルペン成分を回収する工程とを含む。
6個の酵母懸濁物サンプルを以下の組成に調製した。
1.標準的な組成物である酵母グルカン粒子(テルペンを添加しない。)。
2.標準的な組成物と、1g/lゲラニオール。
3.標準的な組成物と、1g/lオイゲノール。
4.標準的な組成物と、1g/lカルボン。
5.標準的な組成物と、1g/lシトラール。
6.標準的な組成物と、1g/lチモール。
Claims (90)
- 微粒子成分と;場合により、封入された活性な薬剤と;防腐性となる量の1種類以上のテルペンとを含む、組成物。
- 組成物は、微粒子成分中に封入された活性な薬剤を含む、請求項1に記載の組成物。
- 防腐性となる量の1種類以上のテルペンは、抗真菌性となる量である、請求項1または2に記載の組成物。
- 1種類以上のテルペンの防腐性となる量は、1%(w/w)以下である、請求項1から3のいずれか一項に記載の組成物。
- 1種類以上のテルペンの防腐性となる量は、約0.01%(w/w)から約0.99%(w/w)である、請求項1から4のいずれか一項に記載の組成物。
- テルペンは、シトラール、ピネン、ネロール、b−イオノン、ゲラニオール、カルバクロール、オイゲノール、カルボン(例えば、L−カルボン)、テルペニオール、アネトール、ショウノウ、メントール、チモール、リモネン、ネロリドール、ファルネソール、フィトール、カロテン(ビタミンA1)、スクアレン、チモール、トコトリエノール、ペリリルアルコール、ボルネオール、ミルセン、シメン、カレン、テルペネン、リナロールおよびこれらの混合物からなる群から選択される、請求項1から5のいずれか一項に記載の組成物。
- テルペンが、ゲラニオール、オイゲノール、カルボン、シトラールおよびチモールからなる群から選択される、請求項1から6のいずれか一項に記載の組成物。
- テルペンは、100%のチモール;100%のゲラニオール;100%のオイゲノール;100%のシトラール;または100%のL−カルボンを含む、請求項1から7のいずれか一項に記載の殺虫組成物。
- テルペンがゲラニオールを含む、請求項1から8のいずれか一項に記載の組成物。
- テルペンが、100%(w/w)のゲラニオールである、請求項9に記載の組成物。
- テルペンがオイゲノールを含む、請求項1から8のいずれか一項に記載の組成物。
- テルペンが、100%(w/w)のオイゲノールである、請求項11に記載の組成物。
- テルペンがカルボンを含む、請求項1から8のいずれか一項に記載の組成物。
- テルペンが、100%(w/w)のカルボンである、請求項13に記載の組成物。
- テルペンがシトラールを含む、請求項1から8のいずれか一項に記載の組成物。
- テルペンが、100%(w/w)のシトラールである、請求項15に記載の組成物。
- テルペンがチモールを含む、請求項1から8のいずれか一項に記載の組成物。
- テルペンが、100%(w/w)のチモールである、請求項17に記載の組成物。
- 微粒子成分が、マイクロカプセル、マイクロ球、リポソーム、酵母細胞粒子およびグルカン粒子およびこれらの混合物からなる群から選択される、請求項1から18のいずれか一項に記載の組成物。
- 微粒子成分が、酵母細胞粒子またはグルカン粒子を含む、請求項1から19のいずれか一項に記載の組成物。
- 微粒子成分が、酵母細胞粒子またはグルカン粒子を含み、これらが無傷である、請求項1から20のいずれか一項に記載の組成物。
- 微粒子成分が、酵母細胞粒子またはグルカン粒子を含み、これらが生きている、請求項1から21のいずれか一項に記載の組成物。
- 微粒子成分が、中空の酵母細胞粒子または中空のグルカン粒子を含む、請求項1から21のいずれか一項に記載の組成物。
- 微粒子成分は、サッカロマイセス セレビシエ(Saccharomyces cerevisiae)の抽出物を含む中空の酵母細胞粒子を含む、請求項1から23のいずれか一項に記載の組成物。
- 微粒子成分は、パン酵母細胞から誘導される中空の酵母細胞粒子を含む、請求項1から24のいずれか一項に記載の組成物。
- テルペン成分が細胞エンベロープ内に保持される、請求項20から25のいずれか一項に記載の組成物。
- テルペン成分が、中空の微粒子内に封入される、請求項20から25のいずれか一項に記載の組成物。
- 中空のグルカン粒子内のベータ1,3−グルカンの量は、約25から約90%(w/w)である、請求項20から27のいずれか一項に記載の組成物。
- 中空のグルカン粒子または細胞壁粒子は、わずかな脂質含有量を有する、請求項20から28のいずれか一項に記載の組成物。
- 脂質含有量は、1%(w/w)以上である、請求項29に記載の組成物。
- 脂質含有量は、約1%から約25%(w/w)である、請求項29または30に記載の組成物。
- 活性な薬剤が、生物学的に活性な薬剤である、請求項1から31のいずれか一項に記載の組成物。
- 生物学的に活性な薬剤が、医薬的に活性な薬剤である、請求項32に記載の組成物。
- 生物学的に活性な薬剤が、殺虫剤、植物栄養物質または植物成長制御剤である、請求項32に記載の組成物。
- 殺虫剤が、除草剤、殺昆虫剤または殺真菌剤である、請求項34に記載の組成物。
- 殺虫剤が除草剤である、請求項34または35に記載の組成物。
- 殺虫剤が殺昆虫剤である、請求項34または35に記載の組成物。
- 殺虫剤が殺真菌剤である、請求項34または35に記載の組成物。
- 活性な薬剤が香料である、請求項1から31のいずれか一項に記載の組成物。
- 活性な薬剤が、食品香味料である、請求項1から31のいずれか一項に記載の組成物。
- 組成物は、組成物全体を基準として、約1ppmから約25ppt(25,000ppm)の活性な薬剤成分を含む、請求項1から40のいずれか一項に記載の組成物。
- 組成物は、組成物全体を基準として、約1%(w/w)から約90%(w/w)の活性な薬剤成分を含む、請求項1から41のいずれか一項に記載の組成物。
- 活性な薬剤成分が、界面活性剤と会合する、請求項1から42のいずれか一項に記載の組成物。
- 組成物が、約500から約10,000ppmの微粒子を含む、請求項1から43のいずれか一項に記載の組成物。
- 組成物が酸化防止剤を含む、請求項1から44のいずれか一項に記載の組成物。
- 組成物が、乾燥粉末の形態である、請求項1から45のいずれか一項に記載の組成物。
- 微粒子と、封入された活性な薬剤と、防腐性となる量のテルペン成分とを含む、微粒子送達系。
- 微粒子が、中空の酵母細胞粒子または中空のグルカン粒子を含む、請求項47に記載の微粒子送達系。
- 溶媒系を含む、請求項47または48に記載の微粒子送達系。
- 溶媒系が水を含む、請求項47から49のいずれか一項に記載の微粒子送達系。
- 受容者に活性な薬剤を送達する方法であって、
(i)防腐性となる量の1種類以上のテルペンを含む微粒子成分を提供する工程と;
(ii)微粒子と活性な薬剤とを接触させ、この活性な薬剤が、少なくとも部分的に微粒子内に封入されるようになる工程と;
(iii)受容者と、活性な薬剤を封入する微粒子成分とを接触させる工程とを含む、方法。 - 受容者は、1つ以上の細胞、哺乳動物、鳥類、魚類、節足動物または植物を含む、請求項51に記載の方法。
- 受容者が哺乳動物である、請求項51または52に記載の方法。
- 哺乳動物は、ヒト、ウシ、ヒツジ、イノシシ、ウマ、イヌおよびネコの種から選択される、請求項53に記載の方法。
- 哺乳動物がヒトである、請求項53または54に記載の方法。
- 受容者が節足動物である、請求項51または52に記載の方法。
- 節足動物が、昆虫またはクモである、請求項56に記載の方法。
- 個体の細胞と、防腐性となる量の1種類以上のテルペンおよび活性な薬剤を含む微粒子成分を含む組成物とを接触させることによって、細胞に有効な量の活性な薬剤を投与する工程を含む、活性な薬剤を用いて身体を治療する方法。
- 身体が、哺乳動物の身体である、請求項58に記載の方法。
- 哺乳動物がヒトである、請求項58または59に記載の方法。
- ある障害を患う患者を治療する方法であって、方法は、微粒子成分内に封入された活性な薬剤を含む組成物の形態で、有効な量の活性な薬剤を投与することを含み;微粒子成分は、防腐性となる量の1種類以上のテルペンを含み、活性な薬剤は、医薬的に活性な薬剤である、方法。
- ペストを殺す方法であって、方法は、微粒子成分内に封入された活性な薬剤を含む組成物の形態で、有効な量の活性な薬剤を投与することを含み;微粒子成分は、防腐性となる量の1種類以上のテルペンを含み、活性な薬剤は、ペストに活性な薬剤である、方法。
- ペストが節足動物である、請求項62に記載のペストを殺す方法。
- ペストが昆虫である、請求項62または63に記載のペストを殺す方法。
- ペストがクモである、請求項62または63に記載のペストを殺す方法。
- ペストがげっ歯動物である、請求項62に記載のペストを殺す方法。
- ペストが真菌類である、請求項62に記載のペストを殺す方法。
- ペストが細菌類である、請求項62に記載のペストを殺す方法。
- ペストが植物である、請求項62に記載のペストを殺す方法。
- 請求項47から50のいずれか一項に記載の微粒子送達系を製造する方法であって、方法は、
微粒子、例えば、β−グルカンを含む抽出された酵母細胞壁を提供し、酵母細胞壁が内部空間の輪郭を形成する工程と;
微粒子と防腐性となる量のテルペン成分とを接触させ、テルペン成分が微粒子と会合するようになる工程と;
微粒子と活性な薬剤とを接触させ、活性な薬剤が微粒子と会合するようになる工程とを含む、方法。 - 治療に有効な量の封入された医薬的に活性な薬剤と、防腐性となる量の1種類以上のテルペンとを含む医薬組成物を調製する方法であって、方法が、マイクロカプセル成分と、活性な薬剤および防腐性となる量のテルペン成分とを混合することを含む、方法。
- 微粒子成分が、中空の酵母細胞粒子または中空のグルカン粒子を含む、請求項71に記載の方法。
- ペストに有効な量の封入されたペストに活性な薬剤と、防腐性となる量の1種類以上のテルペンとを含む殺虫組成物を調製する方法であって、マイクロカプセル成分と、活性な薬剤および防腐性となる量のテルペン成分とを混合することを含む、方法。
- 微粒子成分が、中空の酵母細胞粒子または中空のグルカン粒子を含む、請求項73に記載の方法。
- 微粒子成分と、防腐性となる量の1種類以上のテルペンとを含む、組成物。
- 微粒子内の望ましくないカビ、酵母、および/または真菌の成長の阻害または防止におけるテルペン成分の使用。
- 微粒子が、グルカン粒子または酵母粒子を含む、請求項76に記載の使用。
- 微粒子が、中空のグルカン粒子または中空の酵母粒子を含む、請求項76または77に記載の使用。
- テルペン成分を1%(w/w)以下含む、請求項76から78のいずれか一項に記載の使用。
- 微粒子内の望ましくないカビ、酵母、および/または真菌の成長を阻害または防止する方法であって、方法が、微粒子を、防腐性となる量のテルペン成分で処理することを含む、方法。
- 微粒子が、グルカン粒子または酵母粒子を含む、請求項80に記載の方法。
- 微粒子は、中空のグルカン粒子または中空の酵母粒子を含む、請求項80または81に記載の方法。
- テルペン成分が、1%(w/w)以下含まれる、請求項80から82のいずれか一項に記載の方法。
- 防腐処理された微粒子組成物の製造におけるテルペンの使用。
- 微粒子が、グルカン粒子または酵母粒子を含む、請求項84に記載の使用。
- 微粒子が、中空のグルカン粒子または中空の酵母粒子を含む、請求項84または85に記載の使用。
- テルペン成分が1%(w/w)以下含まれる、請求項84から86のいずれか一項に記載の使用。
- 医薬的に活性な薬剤を含む容器と、微粒子を含む容器とを備える、医薬キット。
- ペストに活性な薬剤を含む容器と、微粒子を含む容器とを備える、ペスト用キット。
- 添付の実施例を参照しつつ明細書に記載されているような実質的な組成物、方法または使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1220940.9A GB201220940D0 (en) | 2012-11-21 | 2012-11-21 | Method P |
GB1220940.9 | 2012-11-21 | ||
PCT/GB2013/053065 WO2014080199A2 (en) | 2012-11-21 | 2013-11-21 | Preservatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016503427A true JP2016503427A (ja) | 2016-02-04 |
JP2016503427A5 JP2016503427A5 (ja) | 2017-01-05 |
JP6622089B2 JP6622089B2 (ja) | 2019-12-18 |
Family
ID=47521503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015543520A Active JP6622089B2 (ja) | 2012-11-21 | 2013-11-21 | 防腐剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10383329B2 (ja) |
EP (1) | EP2922397B8 (ja) |
JP (1) | JP6622089B2 (ja) |
AP (1) | AP2015008522A0 (ja) |
AU (1) | AU2013349461B2 (ja) |
BR (1) | BR112015011743B1 (ja) |
ES (1) | ES2856678T3 (ja) |
GB (1) | GB201220940D0 (ja) |
IL (1) | IL238941B (ja) |
MA (1) | MA38216A1 (ja) |
PL (1) | PL2922397T3 (ja) |
PT (1) | PT2922397T (ja) |
WO (1) | WO2014080199A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2899590T3 (es) | 2004-01-23 | 2022-03-14 | Eden Research Plc | Métodos de eliminación de nematodos que comprenden la aplicación de un componente terpénico |
EP2338332B1 (en) | 2004-05-20 | 2014-02-12 | Eden Research Plc | Hollow glucan particle or cell wall particle encapsulating a terpene component |
KR20140103191A (ko) | 2005-11-30 | 2014-08-25 | 에덴 리서치 피엘씨 | 티몰, 유게놀, 게라니올, 시트랄, 및 l―카르본에서 선택된 테르펜 또는 테르펜 혼합물을 포함하는 조성물 및 방법 |
WO2007063267A1 (en) | 2005-11-30 | 2007-06-07 | Eden Research Plc | Terpene-containing compositions and methods of making and using them |
GB201220940D0 (en) | 2012-11-21 | 2013-01-02 | Eden Research Plc | Method P |
US9510599B2 (en) | 2013-07-25 | 2016-12-06 | Osmose Utilities Services, Inc. | Dazomet compositions |
GB201501793D0 (en) * | 2015-02-03 | 2015-03-18 | Eden Research Plc | Encapsulation of high potency active agents |
US11337422B2 (en) * | 2015-04-17 | 2022-05-24 | Unm Rainforest Innovations | Non-toxic larvicide |
US10555519B2 (en) * | 2015-04-17 | 2020-02-11 | Stc.Unm | Non-toxic larvicide |
CN105919971B (zh) * | 2016-06-23 | 2020-04-24 | 潘元明 | 一种黄连素葡聚糖微胶囊及其制备方法和应用 |
JP2024504059A (ja) | 2021-01-21 | 2024-01-30 | ジェイピー ラボラトリーズ インコーポレイテッド | 食物の貯蔵寿命を延長するための材料および方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001233710A (ja) * | 2000-02-28 | 2001-08-28 | Topics:Kk | マイクロカプセル及びマイクロカプセルの使用方法 |
JP2002188067A (ja) * | 2000-12-19 | 2002-07-05 | Kikusui Tape Kk | 機能性粘着組成物およびそれを用いた機能性粘着材 |
JP2007538062A (ja) * | 2004-05-20 | 2007-12-27 | エーデン リサーチ ピーエルシー | テルペン成分封入中空グルカン粒子または細胞壁粒子を含有する組成物、それらを製造および使用する方法 |
JP2008503472A (ja) * | 2004-06-16 | 2008-02-07 | ゲーリー アール. オストロフ、 | 薬物送達製品および方法 |
JP2009517447A (ja) * | 2005-11-30 | 2009-04-30 | エーデン リサーチ ピーエルシー | チモール、オイゲノール、ゲラニオール、シトラール、及びl−カルボンから選択されたテルペン又はテルペン混合物を含む組成物及び方法 |
JP2009517446A (ja) * | 2005-11-30 | 2009-04-30 | エーデン リサーチ ピーエルシー | テルペン含有組成物とその作製方法及び使用方法 |
Family Cites Families (199)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3499765A (en) | 1966-11-09 | 1970-03-10 | Andrew T Lendvay | Method of improving the flavor of baked goods and goods made by the method |
LU57907A1 (ja) | 1969-02-04 | 1970-08-04 | ||
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
DE2144936B2 (de) | 1970-10-20 | 1974-02-21 | Ciba-Geigy Ag, Basel (Schweiz) | Terpen-aryläther, Verfahren zu deren Herstellung und diese enthaltende Schädlingsbekämpfungsmittel |
US3767421A (en) | 1971-01-19 | 1973-10-23 | Gen Mills Inc | Shelf stable, intermediate moisture doughs |
US3956485A (en) | 1974-02-15 | 1976-05-11 | Research Corporation | Hatching agent for sugar beet nematode |
US4032551A (en) | 1974-02-15 | 1977-06-28 | Research Corporation | Method of obtaining neutral lipid material used as a hatching agent for sugar beet nematode |
US4049828A (en) | 1974-08-05 | 1977-09-20 | Cole Larry K | Insecticidal and insect-repellant methods and compositions |
US4001480A (en) | 1974-08-16 | 1977-01-04 | Swift & Company | Encapsulation process utilizing microorganisms and products produced thereby |
GB1521413A (en) | 1975-03-11 | 1978-08-16 | Sterling Drug Inc | Insecticidal composition |
JPS5432636A (en) | 1977-08-12 | 1979-03-10 | Toyota Matsunaga | Bathing agent composition for treating skin desease |
JPS5564736A (en) | 1978-11-07 | 1980-05-15 | Tadayuki Yoshida | Controlling of soil nematode |
US4310554A (en) | 1979-07-10 | 1982-01-12 | Wisconsin Alumni Research Foundation | Preparation of cheese with microencapsulated enzymes |
JPS5656187A (en) | 1979-10-13 | 1981-05-18 | Ricoh Co Ltd | Amplifier for driving servo motor |
JPS5656184A (en) | 1979-10-12 | 1981-05-18 | Toshiba Corp | Control device for synchronous motor |
JPS5656193A (en) | 1979-10-13 | 1981-05-18 | Mitsubishi Electric Corp | Field current control device |
JPS5673005A (en) | 1979-11-16 | 1981-06-17 | Kuraray Co Ltd | Fungicide for agriculture and horticulture containing terpene carbonyl compound as effective component |
EP0085805B1 (en) | 1981-11-21 | 1986-03-12 | Dunlop Limited | Process for encapsulating substances by means of microorganisms, and the encapsulated products obtained thereby |
NL8203963A (nl) | 1982-10-14 | 1984-05-01 | Naarden International Nv | Werkwijze voor het aromatiseren van droog plantaardig materiaal. |
JPS6047717A (ja) | 1983-08-26 | 1985-03-15 | Nippon Denso Co Ltd | ショックアブソ−バ制御装置 |
JPS60146803A (ja) | 1984-01-06 | 1985-08-02 | Kiyoshi Saotome | 植物病原性細菌の発芽増殖阻害剤 |
US4611608A (en) | 1984-01-13 | 1986-09-16 | Naarden International N.V. | Process for utilizing tobacco dust |
GB2162147A (en) | 1984-07-26 | 1986-01-29 | Dunlop Ltd | Encapsulation and encapsulated products |
JPS6152832A (ja) | 1984-08-24 | 1986-03-15 | 松下電器産業株式会社 | 電気掃除機のバンパ− |
US4696863A (en) | 1984-08-28 | 1987-09-29 | Mitsubishi Paper Mills, Ltd. | Biocapsule |
US4810646A (en) | 1984-11-28 | 1989-03-07 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
US4992540A (en) | 1984-11-28 | 1991-02-12 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US5028703A (en) | 1988-03-11 | 1991-07-02 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US5082936A (en) | 1984-11-28 | 1992-01-21 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
JPS61207139A (ja) | 1985-03-09 | 1986-09-13 | 松下電工株式会社 | 電池式電気機器用スイツチ |
US4743620A (en) | 1985-09-12 | 1988-05-10 | Byron Hodgin | Formulation for the control of nematodes |
US4826693A (en) | 1985-10-29 | 1989-05-02 | Smith Paul F | Manufacture of cheese flavor powder |
GB8608964D0 (en) | 1986-04-12 | 1986-05-14 | Pannell N A | Producing microbially encapsulated materials |
US5288632A (en) | 1986-04-12 | 1994-02-22 | Ad2 Limited | Encapsulation of material in microbial cells |
JPS62294079A (ja) | 1986-06-11 | 1987-12-21 | Mitsubishi Paper Mills Ltd | マイクロカプセルの製造方法 |
DK352187A (da) | 1986-07-09 | 1988-01-10 | Monsanto Co | Vanddispergerbart granulat og fremgangsmaade til fremstilling deraf |
JPH0813729B2 (ja) | 1987-03-06 | 1996-02-14 | 有恒薬品工業株式会社 | 害虫駆除用毒餌剤 |
JPS63299449A (ja) | 1987-05-29 | 1988-12-06 | Toshiba Electric Equip Corp | テレコントロ−ル装置 |
JPH0818937B2 (ja) | 1987-07-06 | 1996-02-28 | 住友化学工業株式会社 | 農園芸用有機燐系殺虫組成物 |
US5001155A (en) | 1987-09-03 | 1991-03-19 | University Of Kentucky Research Foundation | β-ionone derivative as antifungal agent |
US4963583A (en) | 1987-10-05 | 1990-10-16 | Ciba-Geigy Corporation | Beta-ionone derivatives as antifungal agents |
JPH0227903A (ja) | 1988-07-18 | 1990-01-30 | Kubota Ltd | トラクタの油圧配管構造 |
JPH0267208A (ja) | 1988-09-01 | 1990-03-07 | Hokko Chem Ind Co Ltd | 農園芸用殺菌剤 |
JPH02191961A (ja) | 1988-10-05 | 1990-07-27 | Seiko Epson Corp | 電子写真感光体の製造方法 |
US5013566A (en) | 1988-12-19 | 1991-05-07 | Sampson Michael James | Process for obtaining improved yields from plants used for hay making by using a coating agent |
US5091200A (en) | 1989-01-10 | 1992-02-25 | International Flavors & Fragrances Inc. | Process for microwave browning uncooked baked goods foodstuffs |
US4985261A (en) | 1989-01-10 | 1991-01-15 | International Flavors & Fragrances Inc. | Process for microwave browning proteinaceous fibrous meat products |
JPH02214404A (ja) | 1989-02-14 | 1990-08-27 | Furukawa Electric Co Ltd:The | 浮上プラント用長尺体立上げ布設方法 |
US5068453A (en) | 1989-03-13 | 1991-11-26 | Daikin Industries, Ltd. | Novel monoterpenes |
US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US4944693A (en) | 1989-07-28 | 1990-07-31 | Amp Incorporated | Latch arm for electrical connector housing |
GB8917626D0 (en) | 1989-08-02 | 1989-09-20 | Quest Int | Perfumed bleach compositions |
GB8917628D0 (en) | 1989-08-02 | 1989-09-20 | Quest Int | Perfumed fabric softening compositions |
GB9001108D0 (en) | 1990-01-18 | 1990-03-21 | British Textile Tech | Treating materials |
JPH03212497A (ja) | 1990-01-18 | 1991-09-18 | Nippon Alpha Metals Kk | 洗浄組成物 |
JPH0445981A (ja) | 1990-06-14 | 1992-02-14 | Brother Ind Ltd | プリント方法 |
WO1991017741A1 (en) | 1990-05-18 | 1991-11-28 | Peterson Ray L | Waste and odor mitigation composition and substrate |
EP0460945B1 (en) | 1990-06-05 | 1995-10-11 | Mitsubishi Paper Mills, Ltd. | Process for producing microcapsules |
CA2040374C (en) | 1990-07-06 | 1998-06-16 | Gunnar Rorstad | Process for enhancing the resistance of aquatic animals to disease |
GB9022560D0 (en) | 1990-10-17 | 1990-11-28 | G B Biotechnology Limited | Processing of waste |
US5227183A (en) | 1990-12-24 | 1993-07-13 | Mccormick & Company, Inc. | Process for preparing dehydrated aromatic plant products and the resulting products |
KR950010719B1 (ko) | 1991-05-10 | 1995-09-22 | 오르간 하리 가부시끼가이샤 | 재봉틀 바늘 및 그 제조방법 |
JPH06116111A (ja) | 1991-06-28 | 1994-04-26 | Nippon Getsutou Kk | 農業用殺菌剤 |
ATE121594T1 (de) | 1991-08-16 | 1995-05-15 | Quest Int Nederland | Kaugummi mit verbesserter geschmacksfreigabe. |
TW202378B (ja) | 1991-09-11 | 1993-03-21 | Ciba Geigy Ag | |
CA2076466C (en) | 1991-10-21 | 2002-01-15 | Alan R. Tannenbaum | Method for buffering high bandwidth data from an input device |
JPH05139924A (ja) | 1991-11-25 | 1993-06-08 | Itouen:Kk | 天然成分を有効成分とする植物病害防除剤 |
JPH05236941A (ja) | 1992-02-28 | 1993-09-17 | Yuukishitsu Hiryo Seibutsu Kassei Riyou Gijutsu Kenkyu Kumiai | 連作障害軽減材 |
ZA933185B (en) | 1992-05-08 | 1994-05-23 | Dick Co Ab | Encapsulated magnetic particles pigments and carbon black compositions and methods related thereto |
AU5335094A (en) | 1992-11-02 | 1994-05-24 | Quest International B.V. | Tobacco material containing micro-organism cells |
JPH06239715A (ja) | 1993-02-15 | 1994-08-30 | Biotech Kk | 有害微生物の増殖抑制組成物 |
CN1159158A (zh) | 1994-05-20 | 1997-09-10 | 诺瓦瓦克斯有限公司 | 抗菌水包油乳液 |
US5549901A (en) | 1994-05-20 | 1996-08-27 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
US5547677A (en) | 1994-05-20 | 1996-08-20 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
CA2141761A1 (en) | 1994-08-23 | 1996-02-24 | Lanny U. Franklin | Ionone disinfectant |
JP3769057B2 (ja) | 1994-11-17 | 2006-04-19 | 麒麟麦酒株式会社 | マイクロカプセルの製造方法 |
DE19536907C2 (de) | 1995-01-11 | 1998-03-19 | Pro Eff Gmbh Entwicklung Von P | Gerät zur maschinellen Ummantelung von Kabeln, Kabelbäumen oder Leitungen |
US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
US5662915A (en) | 1995-02-01 | 1997-09-02 | Okioga; David Mocheo | Pesticide product derived from the plant Tagetes minuta |
KR19980702014A (ko) | 1995-02-08 | 1998-07-15 | 모리시타 타다시 | 항균성 테르펜 화합물 및 그 제조방법 |
US5730989A (en) | 1995-02-16 | 1998-03-24 | Novavax, Inc. | Oral vaccine against gram negative bacterial infection |
AUPN166195A0 (en) | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
GB9509937D0 (en) | 1995-05-17 | 1995-07-12 | Cpc International Inc | Encapsulated product |
US5622548A (en) | 1995-05-19 | 1997-04-22 | Micap Technology Corp. | Duplicating inks for digital duplicators |
US5756136A (en) | 1995-06-02 | 1998-05-26 | Mccormick & Company, Inc. | Controlled release encapsulation compositions |
US5981625A (en) | 1995-06-23 | 1999-11-09 | Videojet Systems International, Inc. | Non-rub off printing inks |
AUPN398295A0 (en) | 1995-07-05 | 1995-07-27 | Carlton And United Breweries Limited | Chemical compounds and processes for their production |
JPH0967205A (ja) | 1995-08-31 | 1997-03-11 | Sumitomo Chem Co Ltd | 粒状農薬組成物およびその製造方法 |
US5922121A (en) | 1995-10-03 | 1999-07-13 | Videojet Systems International, Inc. | Hydrophobic treatment of pigments |
JPH09114787A (ja) | 1995-10-23 | 1997-05-02 | Nippon Telegr & Teleph Corp <Ntt> | 情報流通方法及びシステム |
US5919838A (en) | 1995-11-02 | 1999-07-06 | Mizobuchi; Yoshikazu | Method for preparing ink concentrates |
DE19546520A1 (de) | 1995-12-13 | 1997-06-19 | Hoechst Ag | Neue Derivate des 2,3,6-Trifluorphenols und ein Verfahren zu ihrer Herstellung |
US6506906B1 (en) | 1996-02-26 | 2003-01-14 | California Institute Of Technology | Preparation and use of bifunctional molecules having DNA sequence binding specificity |
IE80657B1 (en) | 1996-03-29 | 1998-11-04 | Merial Sas | Insecticidal combination to control mammal fleas in particular fleas on cats and dogs |
US5662957A (en) | 1996-05-03 | 1997-09-02 | Novavax, Inc. | Oil containing lipid vesicles with marine applications |
US5700679A (en) | 1996-06-07 | 1997-12-23 | Novavax, Inc. | Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity |
WO1997047288A1 (en) | 1996-06-14 | 1997-12-18 | Emisphere Technologies, Inc. | Microencapsulated fragrances and method for preparation |
US6232528B1 (en) | 1996-06-26 | 2001-05-15 | University Of Florida Research Foundation Incorporated | Disease resistance in vitis |
JPH1076155A (ja) | 1996-09-02 | 1998-03-24 | Kirin Brewery Co Ltd | 非脂溶性物質含有マイクロカプセルおよびその製造方法 |
JPH10164986A (ja) | 1996-12-13 | 1998-06-23 | Murata Makoto | 植物の病気を予防または治療する方法 |
US5939050A (en) | 1997-04-04 | 1999-08-17 | Optiva Corp. | Antimicrobial compositions |
US6156330A (en) | 1997-05-14 | 2000-12-05 | Japan As Represented By Director General Of National Institute Of Sericultural And Entomological Sciences Ministry Of Agriculture, Forestry And Fisheries | Chitin beads, chitosan beads, process for preparing these beads, carrier comprising said beads, and process for preparing microsporidian spore |
DE19720604A1 (de) | 1997-05-16 | 1998-11-19 | Pro Pack Handels Und Vertriebs | Citrusterpene enthaltendes Mittel |
JPH10338630A (ja) | 1997-06-06 | 1998-12-22 | Meiji Seika Kaisha Ltd | 精油を用いた真菌感染拡散防止剤 |
AU7825698A (en) | 1997-06-09 | 1998-12-30 | Procter & Gamble Company, The | Perfumed compositions and methods for reducing body odors and excess moisture |
DE69836328T2 (de) | 1997-06-23 | 2007-05-31 | Naturex Inc. | Lagerungsstabile, zitrusaromatisierte zusammensetzungen enthaltend pflanzenextrakte |
US5965612A (en) | 1997-08-22 | 1999-10-12 | Merck & Co., Inc. | 4-cyano-4-deformylsordaricin derivatives |
US6261540B1 (en) | 1997-10-22 | 2001-07-17 | Warner-Lambert Company | Cyclodextrins and hydrogen peroxide in dental products |
WO1999030691A2 (en) | 1997-12-18 | 1999-06-24 | Ato B.V. | Composition for the controlled release of active compounds |
US6130253A (en) | 1998-01-27 | 2000-10-10 | Ximed Group Plc | Terpene based pesticide treatments for killing terrestrial arthropods including, amongst others, lice, lice eggs, mites and ants |
US5977186A (en) | 1998-01-27 | 1999-11-02 | Ximed Group Plc | Terpene treatments for killing lice and lice eggs |
US6723358B1 (en) | 1998-03-23 | 2004-04-20 | General Mills, Inc. | Encapsulation of components into edible products |
GB2337261B (en) | 1998-05-15 | 2002-09-18 | Fsm Technologies Ltd | Separation of nucleic acids |
EP1085812B1 (en) | 1998-05-20 | 2003-09-10 | Enterprise Ireland (trading as Bioresearch Ireland) | Potato cyst nematode controlling factors and their use in agriculture |
JP3349677B2 (ja) | 1998-05-25 | 2002-11-25 | 麒麟麦酒株式会社 | コーティング剤 |
EP1102540B1 (en) | 1998-07-28 | 2005-10-12 | Ecosmart Technologies, Inc. | Synergistic and residual pesticidal compositions containing pyrethum and benzyl alcohol |
US20030194454A1 (en) | 1998-07-28 | 2003-10-16 | Bessette Steven M. | Pesticidal compositions containing rosemary oil and wintergreen oil |
JP2000053923A (ja) | 1998-08-11 | 2000-02-22 | Sekisui Chem Co Ltd | 殺ダニ効果を持つ床用艶出し剤 |
CZ304054B6 (cs) | 1998-08-18 | 2013-09-04 | Fmc Corporation | Kombinace dvou nebo více aktivních slozek pouzívající mikroenkapsulované prostredky |
JP3903609B2 (ja) | 1998-08-24 | 2007-04-11 | 株式会社デンソー | 回転電機の波巻きコイルおよびその製造方法 |
AU1104300A (en) | 1998-10-09 | 2000-05-01 | Auburn University | A natural and safe alternative to fungicides, bacteriocides, nematicides and insecticides for plant protection and against household pests |
FR2784860B1 (fr) | 1998-10-26 | 2000-12-29 | Action Pin | Composition liquide a activite fongicide, bactericide ou bacteriostatique et procedes de preparation et de mise en oeuvre |
US6525356B1 (en) | 1998-12-15 | 2003-02-25 | Nec Corporation | Solid imaging device |
AU3707100A (en) | 1999-02-25 | 2000-09-14 | Van Kampen Group, Inc., The | The use of specific terpenes to kill, impede, render inactive, or inhibit the growth of plants, bacteria, fungi, yeasts, viruses, and insects, parasites |
US6524998B1 (en) | 1999-03-01 | 2003-02-25 | Auburn University | Biological compositions and methods for enhancing plant growth and health and producing disease-suppressive plants |
US6506707B1 (en) | 1999-03-05 | 2003-01-14 | Ecosmart Technologies, Inc. | Herbicidal compositions containing plant essential oils and mixtures or blends thereof |
AU3519300A (en) | 1999-03-10 | 2000-09-28 | Ecosmart Technologies, Inc. | Nematicidal compositions containing plant essential oils and mixtures or blends thereof |
JP2000302606A (ja) | 1999-04-15 | 2000-10-31 | Novartis Ag | 固体農薬のマイクロカプセル、その製造方法及び施用方法 |
US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
US6841577B2 (en) | 1999-04-29 | 2005-01-11 | Ecosmart Technologies, Inc. | Pesticidal activity of plant essential oils and their constituents |
US6110888A (en) | 1999-05-10 | 2000-08-29 | Takasago International Corporation | Substituted phenols as fragrance, flavor and antimicrobial compounds |
GB9911037D0 (en) | 1999-05-13 | 1999-07-14 | Micap Limited | Nicotine delivery service |
AR020576A1 (es) | 1999-06-28 | 2002-05-15 | Ecosmart Technologies Inc | Método para matar ácaros del moho. |
US6246594B1 (en) | 1999-07-23 | 2001-06-12 | Shindengen Electric Manufacturing Co., Ltd. | Switching power supply having low loss characteristics |
GB2352652A (en) | 1999-08-06 | 2001-02-07 | Fsm Technologies Ltd | Pre-treating hollow fibre membranes for micro-organism detection |
DE19940283A1 (de) | 1999-08-25 | 2001-03-01 | Joerg Peter Schuer | Pflanzenschutz |
US6534078B1 (en) | 1999-10-18 | 2003-03-18 | Natural Pest Fx, Inc. | Micro-encapsulated pepper-mustard composition and methods of using the same |
ES2163999B1 (es) | 1999-11-11 | 2003-03-01 | Inabonos Sa | Composicion de origen natural para controlar la patologia post-cosecha de frutas y hortalizas y metodo de aplicacion. |
ATE266761T1 (de) | 1999-12-22 | 2004-05-15 | Unilever Nv | Verfahren und einrichtung zur behandlung von textilwaren |
AR027527A1 (es) | 2000-02-17 | 2003-04-02 | Ecosmart Technologies Inc | Composiciones pesticidas que contienen aceites vegetales esenciales contra el piojo del cuerpo humano |
US20030091657A1 (en) | 2000-03-17 | 2003-05-15 | Helene Chiasson | Plant acaricidal compositions and method using same |
JP2001294505A (ja) | 2000-04-14 | 2001-10-23 | Jukankyo Kojo Jumoku Seibun Riyo Gijutsu Kenkyu Kumiai | 有害生物駆除及び忌避剤並びに徐放材 |
EP1146111A1 (en) | 2000-04-14 | 2001-10-17 | The Procter & Gamble Company | Process of disinfecting a hard-surface with a composition comprising cinnamon oil and/or an active thereof |
JP2001316214A (ja) | 2000-05-11 | 2001-11-13 | Sadayoshi Usuda | 植物病害に対する天然防除剤 |
JP2003534355A (ja) | 2000-05-26 | 2003-11-18 | ザ プロクター アンド ギャンブル カンパニー | 石鹸ベースの農薬 |
JP3970540B2 (ja) | 2000-05-30 | 2007-09-05 | 高砂香料工業株式会社 | コーティング剤およびコーティング粉末 |
EP1161878A1 (en) | 2000-06-07 | 2001-12-12 | CSM Nederland B.V. | Shortenings with improved performance and doughs and baked products containing these |
EP1161883A1 (en) | 2000-06-07 | 2001-12-12 | CSM Nederland B.V. | Flavoured dough systems |
GB0016312D0 (en) | 2000-07-04 | 2000-08-23 | Zylepsis Ltd | Separation method |
US20040054166A1 (en) | 2000-08-03 | 2004-03-18 | Martin Sauter | Isolation of glucan particles and uses thereof |
US7018641B1 (en) | 2000-08-09 | 2006-03-28 | University Of Florida | Materials and methods for the control of plant pathogens |
US20030036725A1 (en) | 2000-09-21 | 2003-02-20 | Gilad Lavi | Reconstitution and injection system |
US6887493B2 (en) | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
WO2002056879A1 (en) | 2001-01-03 | 2002-07-25 | Medpharma Plc | Use of terpenes for the treatment of digestive tract infections |
ATE366301T1 (de) | 2001-02-05 | 2007-07-15 | Millipore Corp | Detektion von mikroorganismen |
JP3557177B2 (ja) | 2001-02-27 | 2004-08-25 | 三洋電機株式会社 | ヘッドホン用立体音響装置および音声信号処理プログラム |
JP4342761B2 (ja) | 2001-04-17 | 2009-10-14 | 花王株式会社 | 殺菌剤組成物 |
PL347279A1 (en) | 2001-04-24 | 2002-11-04 | Kosmetykow Pollena Ewa Sa Fab | Amber-based cosmetic and perfumery articles |
ZA200402367B (en) | 2001-08-28 | 2005-08-30 | Eden Research Plc | Treatment and prevention of infections in plants. |
NZ531492A (en) | 2001-08-28 | 2007-11-30 | Eden Research Plc | Treatment and prevention of fungal, bacterial, mycoplasma and phytoplasma infections in plants comprising terpene compounds in true solution |
IL145767A (en) | 2001-10-04 | 2006-10-31 | Israel State | Microbicidal formulation comprising an essential oil or its derivatives |
US20030130171A1 (en) | 2001-10-30 | 2003-07-10 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant microbial cells |
WO2003041509A1 (fr) | 2001-11-15 | 2003-05-22 | San-Ei Gen F.F.I., Inc. | Microcapsules et compositions pour administration par voie orale contenant ces microcapsules |
US20030180349A1 (en) | 2001-12-07 | 2003-09-25 | Franklin Lanny U. | Respiratory infection prevention and treatment with terpene-containing compositions |
US20050021433A1 (en) * | 2002-02-12 | 2005-01-27 | Hyler Fletcher H. | Diagnostics for agile infrastructure |
WO2003070286A1 (en) | 2002-02-19 | 2003-08-28 | Eden Research Plc | Improvement of indoor air quality and antiseptic composition for use therein |
EP1476194A4 (en) | 2002-02-19 | 2005-05-18 | Eden Research Plc | COMPOSITIONS AND METHOD FOR PRESERVING FOODSTUFFS |
EP1482791B1 (en) | 2002-02-20 | 2010-08-25 | Dusan Dr. Ninkov | Antimicrobial therapeutic compositions and methods of use |
US20040022990A1 (en) | 2002-04-03 | 2004-02-05 | Arif Sitabkhan | Compositions and methods for providing extended release of fragrances and other agents |
GB2387130A (en) | 2002-04-04 | 2003-10-08 | Fluid Technologies Plc | Hollow fibre filter membrane unit with microorganism detector, and associated usage |
US20030191046A1 (en) | 2002-04-09 | 2003-10-09 | Pawlak Krzysztof | Cosmetic and perfume products with amber |
US20030216488A1 (en) | 2002-04-18 | 2003-11-20 | The Procter & Gamble Company | Compositions comprising a dispersant and microcapsules containing an active material |
US7919308B2 (en) | 2002-06-14 | 2011-04-05 | Agilent Technologies, Inc. | Form in place gaskets for assays |
JP3837440B2 (ja) | 2002-06-21 | 2006-10-25 | 三栄源エフ・エフ・アイ株式会社 | チューインガム |
JP4522256B2 (ja) | 2002-08-21 | 2010-08-11 | キリンホールディングス株式会社 | 脱色酵母細胞壁画分 |
AU2003269660A1 (en) * | 2002-10-21 | 2004-05-04 | Givaudan Sa | Pesticidal compositions |
EP1413202A1 (en) | 2002-10-22 | 2004-04-28 | CSM Nederland B.V. | Lipid-encapsulated functional bakery ingredients |
JP2006510731A (ja) | 2002-10-24 | 2006-03-30 | マイカップ ピーエルシー | 標的化送達 |
GB2394416A (en) | 2002-10-24 | 2004-04-28 | Fluid Technologies Plc | Targeted delivery of microbially encapsulated drugs |
GB2395124A (en) | 2002-11-16 | 2004-05-19 | Fluid Technologies Plc | Palatable microcapsules |
GB2399752A (en) | 2003-03-26 | 2004-09-29 | Micap Plc | Pharmaceutical composition comprising a fungal cell or cell fragment as adjuvant |
BRPI0410491A8 (pt) | 2003-04-24 | 2017-10-24 | Univ Vanderbilt | Composições e métodos para o controle de insetos |
GB2406053B (en) | 2003-09-10 | 2008-08-20 | Micap Plc | Antimicrobial composition |
US7226607B2 (en) * | 2003-09-11 | 2007-06-05 | The Procter & Gamble Company | Compositions comprising a dispersant and microcapsules containing an active material and a stabilizer |
CN1897827B (zh) | 2004-01-12 | 2010-08-25 | 弗门尼舍有限公司 | 含有调味微囊的食用产品 |
JP2005200315A (ja) | 2004-01-13 | 2005-07-28 | Fumakilla Ltd | 蒸散性殺ダニ剤 |
ES2899590T3 (es) | 2004-01-23 | 2022-03-14 | Eden Research Plc | Métodos de eliminación de nematodos que comprenden la aplicación de un componente terpénico |
AU2005234989A1 (en) | 2004-04-27 | 2005-11-03 | Micap Plc | Microbial encapsulation |
GB2413495A (en) | 2004-04-27 | 2005-11-02 | Micap Plc | Phytoactive composition |
GB2413563A (en) | 2004-04-27 | 2005-11-02 | Micap Plc | Composition comprising a biocide encapsulated within a fungal cell |
US20060165746A1 (en) | 2005-01-24 | 2006-07-27 | Arie Markus | Formulations containing microencapsulated essential oils |
GB2424408A (en) | 2005-03-24 | 2006-09-27 | Micap Plc | Encapsulation using microbial cells |
JP5461835B2 (ja) | 2005-05-26 | 2014-04-02 | エルジー エレクトロニクス インコーポレイティド | オーディオ信号の符号化/復号化方法及び符号化/復号化装置 |
WO2009013361A1 (es) | 2007-07-23 | 2009-01-29 | Tramat, S.L. | Procedimiento para la obtención de un producto terminado de madera aplicando nanotecnología |
BRPI0816916A2 (pt) | 2007-09-07 | 2014-09-30 | Mevlabs Inc | Formulações e dispositivos para liberação de compostos a artrópodes e microorganismos no interior dos mesmos. |
CA2754434C (en) | 2009-03-04 | 2017-10-24 | Dow Agrosciences Llc | Microencapsulated insecticide formulations |
GB201220940D0 (en) | 2012-11-21 | 2013-01-02 | Eden Research Plc | Method P |
BR112016011711A2 (pt) | 2013-11-21 | 2017-08-08 | Eden Research Plc | Composição pesticida, método para prepará-la e método para matar insetos |
GB201501793D0 (en) | 2015-02-03 | 2015-03-18 | Eden Research Plc | Encapsulation of high potency active agents |
-
2012
- 2012-11-21 GB GBGB1220940.9A patent/GB201220940D0/en not_active Ceased
-
2013
- 2013-11-21 MA MA38216A patent/MA38216A1/fr unknown
- 2013-11-21 US US14/646,171 patent/US10383329B2/en active Active
- 2013-11-21 WO PCT/GB2013/053065 patent/WO2014080199A2/en active Application Filing
- 2013-11-21 PT PT138217021T patent/PT2922397T/pt unknown
- 2013-11-21 BR BR112015011743-0A patent/BR112015011743B1/pt active IP Right Grant
- 2013-11-21 AU AU2013349461A patent/AU2013349461B2/en active Active
- 2013-11-21 JP JP2015543520A patent/JP6622089B2/ja active Active
- 2013-11-21 EP EP13821702.1A patent/EP2922397B8/en active Active
- 2013-11-21 AP AP2015008522A patent/AP2015008522A0/xx unknown
- 2013-11-21 PL PL13821702T patent/PL2922397T3/pl unknown
- 2013-11-21 ES ES13821702T patent/ES2856678T3/es active Active
-
2015
- 2015-05-21 IL IL238941A patent/IL238941B/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001233710A (ja) * | 2000-02-28 | 2001-08-28 | Topics:Kk | マイクロカプセル及びマイクロカプセルの使用方法 |
JP2002188067A (ja) * | 2000-12-19 | 2002-07-05 | Kikusui Tape Kk | 機能性粘着組成物およびそれを用いた機能性粘着材 |
JP2007538062A (ja) * | 2004-05-20 | 2007-12-27 | エーデン リサーチ ピーエルシー | テルペン成分封入中空グルカン粒子または細胞壁粒子を含有する組成物、それらを製造および使用する方法 |
JP2008503472A (ja) * | 2004-06-16 | 2008-02-07 | ゲーリー アール. オストロフ、 | 薬物送達製品および方法 |
JP2009517447A (ja) * | 2005-11-30 | 2009-04-30 | エーデン リサーチ ピーエルシー | チモール、オイゲノール、ゲラニオール、シトラール、及びl−カルボンから選択されたテルペン又はテルペン混合物を含む組成物及び方法 |
JP2009517446A (ja) * | 2005-11-30 | 2009-04-30 | エーデン リサーチ ピーエルシー | テルペン含有組成物とその作製方法及び使用方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2014080199A2 (en) | 2014-05-30 |
EP2922397A2 (en) | 2015-09-30 |
AU2013349461A1 (en) | 2015-07-02 |
AP2015008522A0 (en) | 2015-06-30 |
BR112015011743B1 (pt) | 2020-03-10 |
PT2922397T (pt) | 2021-03-03 |
EP2922397B1 (en) | 2020-12-30 |
WO2014080199A3 (en) | 2014-08-21 |
EP2922397B8 (en) | 2021-03-17 |
AU2013349461B2 (en) | 2017-06-15 |
US10383329B2 (en) | 2019-08-20 |
PL2922397T3 (pl) | 2021-08-02 |
MA38216A1 (fr) | 2016-09-30 |
JP6622089B2 (ja) | 2019-12-18 |
US20150289503A1 (en) | 2015-10-15 |
IL238941A0 (en) | 2015-07-30 |
GB201220940D0 (en) | 2013-01-02 |
BR112015011743A2 (pt) | 2017-07-11 |
IL238941B (en) | 2019-07-31 |
ES2856678T3 (es) | 2021-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6622089B2 (ja) | 防腐剤 | |
US9717240B2 (en) | Applications of microencapsulated essential oils | |
EP1991052B1 (en) | Applications of microencapsulated essential oils | |
CN101420848B (zh) | 微胶囊化精油的应用 | |
AU2016214120B2 (en) | Encapsulation of high potency active agents | |
KR20080093022A (ko) | 테르펜-함유 조성물 및 이들을 제조하고 사용하는 방법 | |
US20160278367A1 (en) | Pesticidal Composition | |
JP2016503427A5 (ja) | ||
JP2018525340A (ja) | 動物に活性剤を送達するための組成物 | |
KR20160070775A (ko) | 해충 구제용 심리스 캡슐 | |
Pajkic | Development of encapsulation methods for biostimulants | |
CN104336032B (zh) | 杀灭红火蚁饵剂 | |
Sheikh et al. | Chapter-2 Encapsulation of Essential Oils |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161117 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161117 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170419 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170721 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170922 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171011 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180615 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180720 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190611 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191121 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6622089 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |